Boston Scientific Corp (BSX) significantly exceeded Street estimates in its second quarter, reporting adjusted earnings of $0.44 per share against a $0.42 consensus and a 5.2% revenue increase year-over-year to $3.24 billion. The medical technology firm's GAAP net profit also rose to $246 million from $172 million, reinforcing its strong operational performance as it provided positive guidance for the upcoming quarter and full year.
Boston Scientific (BSX) delivered a robust second quarter, exceeding analyst expectations and demonstrating solid year-over-year growth. The company reported adjusted earnings of $0.44 per share, surpassing the Thomson Reuters consensus estimate of $0.42. This bottom-line outperformance was supported by a 5.2% increase in revenue, which grew to $3.24 billion from $3.08 billion in the prior-year period. Profitability on a GAAP basis showed significant improvement, with net income rising to $246 million from $172 million. Critically, the company's forward-looking guidance reinforces this positive momentum, projecting next-quarter adjusted EPS between $0.43 and $0.45 and full-year EPS in the range of $1.74 to $1.77. This combination of a current earnings beat and confident forward guidance suggests strong operational execution and sustained demand within its end markets.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
